NeoGenomics Stock News

Raymond James raised the price target on Target Corporation (NYSE: TGT) from $190 to $200. However, Raymond James analyst Bobby Griffin maintained the stock with a Strong Buy. Target shares fell 0.1

Neo Performance Materials Inc. (OTCPK:NOPMF) Q2 2022 Earnings Conference Call August 12, 2022 10:00 AM ET Company Participants Ali Mahdavi - Senior Vice President of Corporate Development and Capital

NeoGenomics (NASDAQ:NEO) has observed the following analyst ratings within the last quarter:   Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 1 0 0 Last 30D

Companies in The News Are: NEO,H,ARMK,AHCO

NeoGenomics, Inc. (NASDAQ:NEO ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Lynn Tetrault – Interim CEO Charlie Eidson – Director of Investor Relations Bill Bon

NeoGenomics (NEO) delivered earnings and revenue surprises of 27.27% and 0.86%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

NeoGenomics (NEO) delivered earnings and revenue surprises of 27.27% and 0.86%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Techne (TECH) delivered earnings and revenue surprises of -0.49% and 0.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NeoGenomics (NEO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Over the past 3 months, 10 analysts have published their opinion on NeoGenomics (NASDAQ:NEO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a com

FT. MYERS, FL / ACCESSWIRE / June 3, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announce

Upgrades Keefe, Bruyette & Woods upgraded the previous rating for Regions Financial Corp (NYSE:RF) from Underperform to Market Perform. For the first quarter, Regions Financial had an EPS of $0.55, c